P148 | Effects of new anti-diabetic drugs (SGLT2-I and GLP1-RA) in patients suffering from type 2 diabetes mellitus complicated by peripheral artery disease undergoing percutaneous transluminal angioplasty

Premises and Purpose of the study: This study explores the impact of SGLT2 inhibitors and GLP-1 receptor agonists on type 2 diabetes mellitus with peripheral artery disease (PAD) patients undergoing percutaneous distal revascularization (PTA). The research aims to assess the short-term effects of these drugs on some clinical parameters and on metabolic balance in this patient population.Materials and Methods: At ‘SS. Annunziata’ Hospital (Taranto),33 patients with T2DM complicated by PAD undergoing PTA were studied. Divided into SGLT2-i and/or GLP1-RA-treated (11) and other kind of treatment (22), clinical parameters (Leriche-Fontaine stage, recurrence of stenosis and the risk of amputation) were assessed at pre-operative (T0) and 6 months post-surgery(T1). Also, blood-chemical parameters (A1C, lipid profile, renal function, CRP) were examined. Results: Significant reductions in A1C, CRP, uric acid and triglyceride values were observed regardless of drug treatment. Further categorization, revealed that at T0 the untreated group had a higher CRP value, higher insulin and lower metformin intake, while the treated group had higher triglyceride values. At T1, the treated group showed better renal function, reduced Leriche-Fontaine stage and fewer amputations than the untreated group. The two-way ANOVA showed a positive impact of treatment with the new drugs on renal function.Conclusions: This study shows SGLT2-i and/or GLP1-1-RA benefits in T2DM patients with PAD: reduced systemic inflammation, improved blood circulation, fewer stenotic recurrences, lower amputation risk.